Symbol Lookup

Tuesday August 04, 2015 3:51 PM ET. Data delayed 15 minutes.
0.21 (3.25%)
Open/Prev Close
Day Range
52-Week Range
Vol/Avg Daily Vol
  • TSX Comp
  • TSX Venture
  • DJIA
  • S&P 500
Price Comparison Chart
Data delayed at least 15 minutes.

Recent News»

0 New Today
CytoSorbents and TekMed Collaborate to Distribute CytoSorb(R) in Australia and New Zealand
8:00AM ET on Thursday Jul 23, 2015 by PR Newswire

CytoSorbents Corporation (NASDAQ: CTSO), a leader in critical care immunotherapy commercializing its CytoSorb(R) extracorporeal cytokine adsorber to control deadly inflammation using blood purification, today announced an exclusive distribution...

Veteran Healthcare Analyst Michael G. Bator Joins CytoSorbents Board of Directors
8:00AM ET on Wednesday Jul 15, 2015 by PR Newswire

CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb(R) blood purification technology to reduce deadly uncontrolled inflammation, today announced that Michael G. Bator has joined the Company...

Company Information

CytoSorbents Corporation is a critical care focused immunotherapy company. The Company utilizes blood purification to modulate inflammation for treating multiple organ failure illnesses and cardiac surgery. The Company's purification technologies are based on biocompatible, porous polymer beads that can remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. The Company's product CytoSorb is approved in the European Union as an extracorporeal cytokine filter, designed to reduce the cytokine storm that could cause inflammation, organ failure and death in common critical illnesses, such as sepsis, burn injury, trauma, lung injury and pancreatitis. The Company also has other products under development based upon its blood purification technology, including HemoDefend, ContrastSorb, DrugSorb, BetaSorb and others. In addition, CytoSorb can be used in conditions, such as cardiac surgery, autoimmune disease flares, among others.


Headquarters7 Deerpark Dr Ste K
MONMOUTH JUNCTION, NJ, United States 08852-1921


Chairman of the BoardAl Kraus
President, Chief Executive Officer, DirectorPhillip Chan
Chief Financial OfficerKathleen Bloch
Chief Operating OfficerVincent Capponi
Chief Medical OfficerRobert Bartlett

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

Stocks Ratings Sample

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

  • INK Company Insider

    Detailed daily analysis of insider activity and holdings for stocks and income trusts listed in Canada, based on filings from SEDI®

  • S&P Capital IQ Stock Report

    S&P Capital IQ's analysts' overview and valuation, with key fundamental, quantitative, and technical analysis.

  • TDSI Morning Action Notes

    Morning Institutional Report of company updates and new recommendations.

Market Cap$163.8MBeta-0.03
Revenue (TTM)$3.8MEPS$-1.15
Shares Out.24.8MBook Value$0.17
Dividend Yield0.00%P/E--
Annual Dividend Rate0.00 USDPrice/Sales (TTM)43.3
Ex-Div Date1/1/01P/Cash Flow (TTM)--
Pay Date1/1/01Operating Margin-233.53%

*GAAP = prior to non-GAAP analyst adjusted earnings.


Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.

Stocks Calendar Sample